PRODUCT MONOGRAPH

PrXEOMIN®

incobotulinumtoxinA

Clostridium Botulinum Neurotoxin Type A (150 kD), free from complexing proteins

Powder for solution for injection
50 and 100 LD$_{50}$ units per vial

Pharmaceutical Standard: House

Muscle relaxant, peripherally acting agent

Manufactured by:
Merz Pharmaceuticals GmbH
Eckenheimer Landstraße 100
60318 Frankfurt/Main
Germany

http://www.merz.com/company/merz_pharmaceuticals/

Imported and distributed by:
Merz Pharma Canada Ltd.
5515 North Service Road, Ste 202
Burlington, ON  L7L 6G4

Control No: 181523

Date of Approval: December 22, 2015
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3
  SUMMARY PRODUCT INFORMATION ........................................................................ 3
  DESCRIPTION ............................................................................................................ 3
  INDICATIONS AND CLINICAL USE ....................................................................... 3
  CONTRAINDICATIONS ............................................................................................. 4
  WARNINGS AND PRECAUTIONS .......................................................................... 5
  ADVERSE REACTIONS ............................................................................................ 8
  DRUG INTERACTIONS .............................................................................................. 15
  DOSAGE AND ADMINISTRATION .......................................................................... 16
  OVERDOSAGE ........................................................................................................ 22
  ACTION AND CLINICAL PHARMACOLOGY ......................................................... 23
  STORAGE AND STABILITY ..................................................................................... 25
  SPECIAL HANDLING INSTRUCTIONS ................................................................. 25
  DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................... 25

PART II: SCIENTIFIC INFORMATION ........................................................................... 27
  PHARMACEUTICAL INFORMATION ....................................................................... 27
  CLINICAL TRIALS ................................................................................................. 29
  DETAILED PHARMACOLOGY ............................................................................... 38
  TOXICOLOGY .......................................................................................................... 41
  REFERENCES ........................................................................................................... 45

PART III: CONSUMER INFORMATION ....................................................................... 47
**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intramuscular injection</td>
<td>Powder for solution for injection</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>50 and 100 LD&lt;sub&gt;50&lt;/sub&gt; units per vial</td>
<td><em>For a complete listing see Dosage Forms, Composition and Packaging section.</em></td>
</tr>
</tbody>
</table>

**DESCRIPTION**

XEOMIN® (incobotulinumtoxinA) is produced by the anaerobic bacterial fermentation process from the Hall strain of *Clostridium botulinum*. It consists of the purified neurotoxin which has been separated from complexing proteins (hemagglutinins and a non-toxic non-hemagglutinating protein) during production. It is a polypeptide comprised of a heavy chain, with a molecular weight of approximately 100 kD, and a light chain, with a molecular weight of approximately 50 kD. These separated chains are covalently linked via a disulphide bond. The light chain is associated with a zinc ion and functions as a zinc-dependent endopeptidase. The heavy chain comprises two functional domains: the N-terminal section is the translocation domain and the C-terminal section is the binding domain.

XEOMIN® is supplied as a sterile, white, preservative free powder for solution for injection (lyophilisate) packed under nitrogen in glass vials. The vials are closed with rubber stoppers and aluminum caps. Each vial contains either 50 or 100 mouse LD<sub>50</sub> units of incobotulinumtoxinA (*Clostridium Botulinum* Neurotoxin Type A (150 kD), free from complexing proteins), 4.7 mg of sucrose and 1.0 mg of human serum albumin. One unit corresponds to the median lethal dose (LD<sub>50</sub>) when the reconstituted product is injected intraperitoneally into mice under defined conditions. Prior to use XEOMIN® is reconstituted with commercially available 0.9 % physiological saline (not supplied in the pack) to form a clear, and colorless solution. The size of the vials allows different concentrations (i.e. doses) to be prepared.

**INDICATIONS AND CLINICAL USE**
XEOMIN® is indicated:

- for the treatment of hypertonicity disorders of the 7th nerve such as blepharospasm including benign essential blepharospasm and hemifacial spasm in adults.
- to reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults
- for the treatment of upper limb spasticity associated with stroke in adults.

XEOMIN® as a treatment for focal spasticity has been studied in association with usual standard care regimens and is not intended as a replacement for these treatment modalities. XEOMIN® is not likely to be effective at a joint affected by a fixed contracture.

XEOMIN® may only be used by physicians with suitable qualifications and experience in the application of Botulinum toxin type A.

**Geriatrics (> 65 years of age):**

Although clinical studies included a number of patients over the age of 65, no clinical trials specifically designed for elderly patients have been performed.

Initial dosing should begin at the lowest recommended dose for the specific indication and be cautiously titrated within the recommended range for optimal patient outcome.

**Pediatrics (< 18 years of age):**

XEOMIN® has not been studied in the paediatric population and is therefore currently not recommended in this age group.

**CONTRAINDICATIONS**

- Hypersensitivity to Botulinum neurotoxin type A or to any of the excipients.
- Generalised disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome).
- Infection or inflammation at the proposed injection site.
WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- The term "unit" or "U" upon which dosing is based, is a specific measurement of toxin activity that is unique to XEOMIN®. Therefore, the "unit" or “U" used to describe XEOMIN® activity are different from those used to describe that of other botulinum toxin preparations and the units representing XEOMIN® activity are not interchangeable with other products.
- XEOMIN® should only be given by physicians with the appropriate qualifications and experience in the treatment and the use of required equipment.
- Follow the recommended dosage and frequency of administration for XEOMIN® (See DOSAGE AND ADMINISTRATION).

General

In very rare cases severe adverse events like exaggerated muscle weakness, dysphagia or aspiration pneumonia with a suspected causal relationship to toxin spread have been reported with the use of botulinum toxin at therapeutic doses. Dysphagia has also been reported following injections to sites other than the cervical musculature. Patients with a neurological underlying disease or swallowing, speech or respiratory difficulties have an increased risk for these adverse drug reactions (see Pre-existing Neuromuscular Disease).

Prior to administering XEOMIN®, the physician must familiarise himself/herself with the patient’s anatomy and any alterations to the anatomy. Care should be taken to ensure that XEOMIN® is not injected into a blood vessel. Undesirable effects may occur from misplaced injections of Botulinum neurotoxin type A that temporarily paralyse nearby muscle groups. There have been reports of undesirable effects that might be related to the spread of the toxin to sites far from the injection site (See ADVERSE REACTIONS). Some of these can be life threatening and there have been reports of death. For the treatment of cervical dystonia and post-stroke spasticity extra caution is required when injecting at sites close to sensitive structures such as the carotid artery, lung apices and esophagus. Failure to correctly target the desired musculature through misplaced applications may likewise result in apparent lack of efficacy.

Clinical effects of XEOMIN® may increase or decrease with repeated injections. Possible reasons for change in clinical effect are different techniques of reconstitution, the chosen injection intervals, the injected muscles and marginally varying toxin activity resulting from the biological testing procedure employed or secondary non-response.

XEOMIN® as a treatment for focal spasticity has been studied in association with usual standard care regimens and is not intended as a replacement for these treatment modalities. XEOMIN® is not likely to be effective at a joint affected by a fixed contracture.

XEOMIN® contains albumin, a derivative of human blood. Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include careful selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the
inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens. There are no reports of viral transmissions with albumin manufactured to European Pharmacopoeia specifications by established processes.

**Gastrointestinal**

**Spasmodic torticollis**

Patients should be informed that injections of XEOMIN® for the management of spasmodic torticollis may cause mild to severe dysphagia with the risk of aspiration and dyspnœa. Medical intervention may be necessary (e.g. in the form of a gastric feeding tube) (See ADVERSE REACTIONS). Dysphagia can last for up to two to three weeks after injection, but a duration of up to five months has been reported in one case. Patients with smaller neck muscle mass, or patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk. The occurrence of dysphagia is attributable to the spread of the pharmacological effect of Botulinum toxin as the result of the neurotoxin spread into the oesophageal musculature.

**Hematologic**

Since XEOMIN® is administered by injection, and pathology may require multiple injections to deep musculature, it should be administered with caution:

- in patients with known bleeding disorders
- in patients receiving anticoagulant therapy or taking other substances at anticoagulant doses.

**Hypersensitivity Reactions**

Hypersensitivity reactions have been reported with Botulinum neurotoxin products. If serious (e.g. anaphylactic reactions) and/or immediate hypersensitivity reactions occur, appropriate medical therapy should be instituted.

**Immune**

The risks for development of neutralizing antibodies to Botulinum toxins have been reported to be related to high dosage, too frequent injections, young age at disease onset, and higher total dosage received of Botulinum toxin. Antibody development may lead to treatment failure (See DOSAGE AND ADMINISTRATION).

**Ophthalmologic**

**Blepharospasm**

Because of the anticholinergic effect of Botulinum toxin type A, XEOMIN® should be used with caution in patients at risk of developing angle closure glaucoma.

Injections near the levator palpebrae superioris should be avoided to reduce the occurrence of
ptosis. Diplopia may develop as a result of Botulinum neurotoxin type A diffusion into the obliquus oculi inferior. Avoiding medial injections into the lower lid may reduce this adverse reaction.

Reduced blinking following XEOMIN® injection into the orbicularis muscle can lead to corneal exposure, persistent epithelial defects and corneal ulceration, especially in patients with cranial nerve disorders (facial nerve). Careful testing of corneal sensation should be performed in patients with previous eye operations. Vigorous treatment of any corneal epithelial defect is necessary. This may require protective drops, ointments, soft bandage contact lenses, or closure of the eye by patching or similar means.

Ecchymosis easily occurs in the soft tissues of the eyelid. Immediate gentle pressure at the injection site can limit that risk.

**Pre-existing Neuromuscular Disorders**

Patients with neuromuscular disorders may be at increased risk of exaggerated muscle weakness. The Botulinum toxin product should be used under specialist supervision in these patients and should only be used if the benefit of treatment is considered to outweigh the risk. Patients with a history of dysphagia and aspiration should be treated with extreme caution. Patients and caregivers should be advised to seek immediate medical consultation if swallowing, speech, or respiratory disorders arise.

XEOMIN® should be used with caution:

- In patients suffering from amyotrophic lateral sclerosis or other diseases which result in peripheral neuromuscular dysfunction
- In targeted muscles which display pronounced weakness or atrophy.

**Special Populations**

**Pregnant Women:**
There have been no studies in pregnant women. Studies in animals have shown reproductive toxicity (See TOXICOLOGY). The potential risk for humans is unknown.

XEOMIN® should not be used during pregnancy unless clearly necessary and unless the potential benefit justifies the risk.

**Nursing Women:**
It is not known whether Botulinum toxin type A is excreted into the breast milk. Therefore, the use of XEOMIN® during lactation is not recommended.

**Pediatrics (< 18 years of age):**
No data is available on the use of XEOMIN® in children and it is therefore currently not recommended in this age group.

**Geriatrics (> 65 years of age):**

---

XEOMIN® - Product Monograph  
Page 7 of 50
Although clinical studies included a number of patients over the age of 65, no clinical trials specifically designed for elderly patients have been performed. Initial dosing should begin at the lowest recommended dose for the specific indication and be cautiously titrated within the recommended range for optimal patient outcome.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Usually, undesirable effects are observed within the first week after treatment and are temporary in nature. They may be related to the active substance, the injection procedure, or both. Undesirable effects associated with the therapeutic use of Botulinum toxin type A are mainly related to the diffusion of Botulinum neurotoxin type A from the target muscle to adjacent muscles. Intramuscular injection into neck muscles for treatment of cervical dystonia occasionally results in transient dysphagia with varying degrees of severity with the potential for aspiration which may require medical intervention. Dysphagia may persist for two to three weeks after injection, but has been reported in one case to last five months. Dysphagia appears to be dose-dependent. Treatment of blepharospasm by periocular injection can result in ptosis and diplopia. Intramuscular injections of Botulinum toxin type A for upper limb spasticity were reported to be commonly associated with pain in shoulder, arm or hand.

Side effects related to spread of toxin distant from the site of administration have been reported very rarely (exaggerated muscle weakness, dysphagia, and aspiration pneumonitis with fatal outcome in some cases).

There have been rare reports of undesirable effects related to the cardiovascular system, such as arrhythmia and myocardial infarction, some with fatal outcomes. It remains unclear whether these deaths were induced by the Botulinum toxin type A- products or whether these were caused by pre-existing cardiovascular disease. Serious and/or immediate hypersensitivity reactions have been rarely reported, including anaphylaxis, serum sickness, urticaria, soft tissue oedema, and dyspnoea. Some of these reactions have been reported following the use of other Botulinum toxin type A-products either alone or in combination with other agents known to cause similar reactions.

QT interval prolongation has been reported in 2 out of 366 patients following administration of XEOMIN® in clinical studies with blepharospasm and cervical dystonia patients. However, these findings were not considered clinically relevant in the opinion of the treating cardiologist and the exact relationship of these events to XEOMIN® is unknown.

Application-related Undesirable Effects

As it is expected for any injection procedure localised pain, inflammation, paresthesia, hypoesthesia, tenderness, swelling, edema, erythema, itching, localised infection, hematoma, bleeding and/or bruising may be associated with the injection.

Needle related pain and/or anxiety may result in vasovagal responses, including transient symptomatic hypotension, anxiety, nausea, tinnitus and syncope.
**Undesirable Effects of the Substance Class Botulinum Toxin Type A**

Localised muscle weakness is one expected pharmacological effect of Botulinum toxin. Likewise failure to correctly apply Botulinum toxin to the targeted muscles at an appropriate dose may result in apparent lack of efficacy.

**Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

In the one phase 2 and seven phase 3 studies conducted to provide data on the safety of XEOMIN®, 1573 patients were treated with trial medications (XEOMIN®, active comparator, or placebo). In these studies 1129 patients received XEOMIN® (555 patients with cervical dystonia [CD], 246 blepharospasm [BLEPH] patients and 328 patients with post-stroke spasticity of the upper limb [PSSUL]). A total of 279 patients in the repeated-dose CD studies, 98 patients in the repeated-dose BLEPH study, and 136 patients in the repeated-dose PSSUL study had at least two injections of XEOMIN®.

The duration of observation was 120 days in the phase 2 study in cervical dystonia. For the phase 3 trials in CD, BLEPH and PSSUL, patients were observed for up to 21 weeks following a single dose injection and for up to 69 weeks following repeated injections in either a Double-Blind Extension Period (CD) or Open-Label Extension (OLEX) Period (BLEPH and PSSUL).

In all active-controlled trials, patients received one dose of either XEOMIN® and/or Active Comparator 1 (onabotulinumtoxinA) with doses ranging from 30 - 300 units in cervical dystonia patients and 15 - 100 units in BLEPH patients.

In the placebo-controlled and OLEX Periods of the pivotal PSSUL study per protocol doses administered ranged from 170 - 400 units. The OLEX Period allowed up to a maximum of five injection intervals. In an additional study in PSSUL, patients were administered up to a maximum single dose of 400 units XEOMIN®. In the placebo-controlled study in CD, doses of 120 and 240 units were administered with these same doses administered in the Double-Blind Extension Period up to a maximum of five injection intervals. In an open-label study in CD, patients were administered doses ranging from 50 – 300 units XEOMIN® for 25 to 121 weeks. In the placebo-controlled study and the subsequent OLEX Period in BLEPH, patients received a maximum of 50 units XEOMIN® per eye with up to six injections. In the repeated-dose studies, dosing intervals were flexible with a minimum interval between two injections of at least six weeks.

The safety profile in the repeated dose studies was similar to that observed in the placebo-controlled single-dose studies. Neither the overall incidence nor the cumulative incidence rate of adverse reactions increased with increasing number of injections in any of the indications.
Tables 1 to 5 summarize adverse drug reactions by indication that occurred in at least 1% of XEOMIN®-treated patients and occurred more frequently than in control patients in the single dose studies.

**Table 1: Adverse Drug Reactions Reported in ≥1% of Cervical Dystonia Patients – Single Dose Placebo-Controlled Study**

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Preferred term</th>
<th>Number of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>XEOMIN® 120 U N=78</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Neck pain</td>
<td>4 (5.1)</td>
</tr>
<tr>
<td></td>
<td>Muscular weakness</td>
<td>5 (6.4)</td>
</tr>
<tr>
<td></td>
<td>Musculoskeletal pain</td>
<td>5 (6.4)</td>
</tr>
<tr>
<td></td>
<td>Musculoskeletal stiffness</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Muscle spasms</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Myalgia</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Musculoskeletal discomfort</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Dysphagia</td>
<td>8 (10.3)</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Dry mouth</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Injection site pain</td>
<td>7 (9.0)</td>
</tr>
<tr>
<td></td>
<td>Asthenia</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Influenza like illness</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Local swelling</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Pain</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Malaise</td>
<td>0</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache</td>
<td>2 (2.6)</td>
</tr>
<tr>
<td>System organ class</td>
<td>Preferred term</td>
<td>XEOMIN® 120 U N=78</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Head discomfort</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Hyperhidrosis</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Erythema</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Skin discolouration</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Dysphonia</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Oropharyngeal pain</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Rhinorrhea</td>
<td>1 (1.3)</td>
</tr>
<tr>
<td></td>
<td>Choking</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Dyspnea</td>
<td>0</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>Influenza</td>
<td>0</td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td>Contusion</td>
<td>1 (1.3)</td>
</tr>
</tbody>
</table>

Table 2: Adverse Drug Reactions Reported in ≥1% of Cervical Dystonia Patients – Single Dose Active-Controlled Studies
<table>
<thead>
<tr>
<th></th>
<th>XEOMIN®</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysphagia</td>
<td>24 (8.8)</td>
<td>15 (6.1)</td>
</tr>
<tr>
<td><strong>Musculoskeletal &amp; connective tissue disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neck pain</td>
<td>5 (1.8)</td>
<td>1 (≤ 1)</td>
</tr>
<tr>
<td>Muscular weakness</td>
<td>4 (1.5)</td>
<td>1 (≤ 1)</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection site pain</td>
<td>3 (1.1)</td>
<td>1 (≤ 1)</td>
</tr>
</tbody>
</table>

Overall in the main and repeated dose periods of two long term studies in cervical dystonia, patients were administered up to six injections of XEOMIN® with a minimum interval between two injections of at least six weeks. Adverse reactions reported in ≥1% of patients after any one injection included dry mouth, dysphagia, dysphonia, headache, head titubation, injection site pain, muscle fatigue, muscle spasms, muscle tightness, muscular weakness, musculoskeletal pain, musculoskeletal stiffness, neck pain, and upper respiratory tract infection.

**Table 3: Adverse Drug Reactions Reported in ≥1% of Blepharospasm Patients – Single Dose Placebo-Controlled Study**

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Number of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred term</td>
<td>XEOMIN®</td>
</tr>
<tr>
<td>N=74</td>
<td>N=34</td>
</tr>
</tbody>
</table>

**XEOMIN® - Product Monograph**
<table>
<thead>
<tr>
<th>System organ class</th>
<th>Preferred term</th>
<th>XEOMIN® N=74</th>
<th>Placebo N=34</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eye disorders</td>
<td>Eyelid ptosis</td>
<td>13 (17.6)</td>
<td>1 (2.9)</td>
</tr>
<tr>
<td></td>
<td>Dry eye</td>
<td>11 (14.9)</td>
<td>3 (8.8)</td>
</tr>
<tr>
<td></td>
<td>Vision blurred</td>
<td>3 (4.1)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Vision impairment</td>
<td>2 (2.7)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Diplopia</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Eye pain</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Lacrimation increased</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Dry mouth</td>
<td>7 (9.5)</td>
<td>1 (2.9)</td>
</tr>
<tr>
<td></td>
<td>Lip disorder</td>
<td>2 (2.7)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Dysphagia</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Injection site pain</td>
<td>3 (4.1)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Headache</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 4: Adverse Drug Reactions Reported in ≥1% of Blepharospasm Patients – Single Dose Active-Controlled Study
Overall in the main and repeated dose periods of the blepharospasm long term study, patients were administered up to six injections of XEOMIN® with a minimum interval between two injections of at least six weeks. Adverse reactions reported in ≥1% of patients after any one injection included asthenia, blepharospasm, diplopia, dry eye, dry mouth, dysphagia, excessive eye blinking, eyelid ptosis, eye pain, facial paresis, fatigue, headache, injection site hematoma, injection site pain, lacrimation increased, lip disorder, muscular weakness, nausea, ocular hyperemia, edema, periorbital hematoma, rash, speech disorder, urticaria, vision blurred, and visual impairment.

Table 5: Adverse Drug Reactions Reported in ≥1% of Patients with Post-stroke Spasticity of the Upper Limb – Single Dose Placebo-Controlled Study

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Preferred term</th>
<th>Number of patients (%)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>XEOMIN® N=73</td>
<td>Placebo N=75</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Dysesthesia</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Hypoesthesia</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Feeling hot</td>
<td>1 (1.4)</td>
<td>0</td>
</tr>
</tbody>
</table>

Overall in the main and repeated dose periods of the long term study in post-stroke spasticity of the upper limb, patients were administered up to six injections of XEOMIN® with a minimum interval between two injections of at least twelve weeks. Adverse reactions reported in ≥1% of
patients after any one injection included dysphagia, injection site pain, muscular weakness, and pain in extremity.

**Less Common Clinical Trial Adverse Drug Reactions (<1%)**

Adverse drug reactions occurring in XEOMIN®-treated patients (<1% but more frequent than in control patients) in the controlled, single-dose studies are included below.

**Cervical Dystonia**

Choking, colitis, contusion, dysphonia, dyspnea, erythema, eye pain, head titubation, influenza like illness, local swelling, malaise, migraine, musculoskeletal discomfort, oropharyngeal pain, pain, paresthesia, pruritus, rash, rhinorrhea, skin discoloration, skin exfoliation, speech disorder, tremor.

**Blepharospasm**

Extraocular muscle paresis, eye pruritus, muscular weakness, paresthesia, periorbital hematoma, prurigo.

**Post-stroke Spasticity of the Upper Limb**

None reported.

**Abnormal Hematologic and Clinical Chemistry Findings**

In all clinical trials, there were no findings indicative of underlying pathological changes as a result of trial medication, both with regard to the incidence of abnormal hematologic and clinical chemistry values and with regard to the mean change in laboratory values for either treatment group.

**Post-Market Adverse Drug Reactions**

The following adverse reactions have been reported since XEOMIN® has been marketed: eye swelling, eyelid edema, madarosis, vision blurred, injection site reactions; asthenia, fatigue, dysphagia, nausea, abdominal distension; hypersensitivity reactions like swelling, edema (also apart from injection site), erythema, pruritus, rash (local and generalized), allergic dermatitis, drug eruptions, lymphadenopathy, alopecia and breathlessness; dysphonia, cough, asthma; herpes zoster; muscular weakness, muscle spasm, myalgia, trismus; dysarthria, somnolence; cardiovascular insufficiency, circulatory collapse; abnormal dreams; flu-like symptoms.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**DRUG INTERACTIONS**

**Drug-Drug Interactions**
No interaction studies have been performed.

Theoretically, the effects of Botulinum toxin may be potentiated by aminoglycoside antibiotics or other medicinal products that interfere with neuromuscular transmission, e.g. tubocurarine-type muscle relaxants.

Therefore, the concomitant use of XEOMIN® with aminoglycosides, polymyxins, tetracyclines, lincomycin, spectinomycin or any other drugs that interfere with neuromuscular transmission requires special care. Peripheral muscle relaxants should be used with caution, if necessary reducing the starting dose of relaxant, or using an intermediate-acting substance such as vecuronium or atracurium rather than substances with longer lasting effects.

4-Aminochinolines may reduce the effect of XEOMIN®.

**Drug-Food Interactions**

Interactions with food are not relevant.

**Drug-Herb Interactions**

Interactions with herbal products have not been established.

**Drug-Laboratory Interactions**

Interactions with results of laboratory tests have not been established.

**Drug-Lifestyle Interactions**

No studies on the effects on the ability to drive and use machines have been performed. However if loss of strength, muscle weakness, blurred vision, tiredness, dizziness or drooping eyelids occur, affected persons should avoid these tasks until they adjust to these changes.

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

- Due to unit differences in the potency assay, XEOMIN® units are specific to XEOMIN®. Therefore unit doses or “U” recommended for XEOMIN® are not interchangeable with those for other preparations of Botulinum toxin.

- XEOMIN® may only be used by physicians with suitable qualifications and experience in the application of Botulinum toxin.

- Reconstituted XEOMIN® is intended for intramuscular injection. After reconstitution, XEOMIN® should be used for only one injection session and for only one patient.
- The minimal injection intervals and the maximum doses of XEOMIN® should be as recommended for the specific indication.

- The optimum dosage and number of injection sites in the treated muscle should be determined by the physician individually for each patient. A titration of the dose should be performed.

- A decrease or increase in the XEOMIN® dose is possible by administering a smaller or larger injection volume. Initial dosing should begin at the lowest recommended dose for the specific indication and be cautiously titrated within the recommended range for optimal patient outcome. The smaller the injection volume the less pressure sensation and the less spread of Botulinum neurotoxin type A in the injected muscle occurs. This is of benefit in reducing effects on nearby muscles when small muscle groups are being injected.

- If no treatment effect occurs within one month after the initial injection, the following measures should be taken:

  There are several potential explanations for a lack of or a diminished response to an individual treatment with XEOMIN®. These may include inadequate dose selection, selection of inappropriate muscles for injection, muscles inaccessible to injection, underlying structural abnormalities such as muscle contractures or bone disorders, change in pattern of muscle involvement, failure to correctly target the desired muscle, patient perception of benefit compared with initial results, inappropriate storage or reconstitution, as well as neutralizing antibodies to Botulinum toxin.

  A suggested course of action when patients do not respond to XEOMIN® injections is:
  1) wait the usual treatment interval;
  2) consider reasons for lack of response listed above;
  3) test patient using an acceptable method (i.e., test for anhydrotic rings with a starch iodine test or test for serum antibodies).

  More than one treatment course should be considered before classification of a patient as a non-responder.

- XEOMIN® has not been studied in the paediatric population and is therefore not recommended in the paediatric age group until further data become available.

**Recommended Dose and Dosage Adjustment**

**Blepharospasm**

The initial recommended dose is 1.25 to 2.5 units (0.05-0.1 mL volume) per injection site. The initial dose should not exceed 35 units per eye for pre-treated patients if the previous dose of Botulinum toxin is not known. For treatment naïve patients the initial dose should not exceed 25 units per eye. In subsequent treatments, dosing units and dosing interval may be titrated for maximum patient benefit. Normally, the total dose should not exceed 100 units per treatment
Median onset of effect is observed four days after injection. The effect of each treatment generally lasts approximately 3-4 months. The period between each treatment session is recommended to be at least 12 weeks. Based on monitoring of patients, there can be flexibility in terms of re-treatment intervals (see CLINICAL TRIALS). Normally, no additional benefit is conferred by treating more frequently than every three months. There is limited experience in treatment naïve patients and in long term repeat dose treatment.

**Spasmodic torticollis**

In practice, the usual total dose does not exceed 200 units. Doses of up to 300 units may be given. No more than 50 units should be given at any one injection site.

Median onset of effect is observed seven days after injection. The effect of each treatment generally lasts approximately 3-4 months. The period between each treatment session is recommended to be at least 12 weeks. Based on monitoring of patients, there can be flexibility in terms of re-treatment intervals (see CLINICAL TRIALS).

**Post-stroke Spasticity of the Upper Limb**

The doses (units) usually administered in the management of post-stroke spasticity of the upper limb are presented in Table 6 and Table 7.

**Table 6: Initial Dosage Guide for the Management of Post-stroke Spasticity of the Upper Limb**

<table>
<thead>
<tr>
<th>Clinical Pattern</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Muscle</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Flexed Wrist</strong> (Total)</td>
<td>90</td>
</tr>
<tr>
<td>Flexor carpi radialis</td>
<td>50</td>
</tr>
<tr>
<td>Flexor carpi ulnaris</td>
<td>40</td>
</tr>
<tr>
<td><strong>Clenched Fist</strong> (Total)</td>
<td>80</td>
</tr>
<tr>
<td>Flexor digitorum superficialis</td>
<td>40</td>
</tr>
<tr>
<td>Flexor digitorum profundus</td>
<td>40</td>
</tr>
<tr>
<td><strong>Flexed Elbow</strong> (Total)</td>
<td>130-190</td>
</tr>
<tr>
<td>Brachioradialis</td>
<td>60</td>
</tr>
<tr>
<td>Biceps</td>
<td>80</td>
</tr>
<tr>
<td>Brachialis</td>
<td>50</td>
</tr>
<tr>
<td><strong>Pronated Forearm</strong> (Total)</td>
<td>25-65</td>
</tr>
<tr>
<td>Pronator quadratus</td>
<td>25</td>
</tr>
<tr>
<td>Pronator teres</td>
<td>40</td>
</tr>
<tr>
<td><strong>Thumb-in-Palm</strong> (Total)</td>
<td>10-40</td>
</tr>
<tr>
<td>Flexor pollicis longus</td>
<td>20</td>
</tr>
<tr>
<td>Adductor pollicis</td>
<td>10</td>
</tr>
<tr>
<td>Flexor pollicis brevis/</td>
<td>10</td>
</tr>
<tr>
<td>Opponens pollicis</td>
<td></td>
</tr>
</tbody>
</table>
Table 7: Repeat Dosage Guide for the Management of Post-stroke Spasticity of the Upper Limb

<table>
<thead>
<tr>
<th>Clinical Pattern</th>
<th>Muscle</th>
<th>Units (Range)</th>
<th>Number of injection sites per muscle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flexed Wrist</td>
<td>Flexor carpi radialis</td>
<td>25-100</td>
<td>1-2</td>
</tr>
<tr>
<td></td>
<td>Flexor carpi ulnaris</td>
<td>20-100</td>
<td>1-2</td>
</tr>
<tr>
<td>Clenched Fist</td>
<td>Flexor digitorum superficialis</td>
<td>40-100</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Flexor digitorum profundus</td>
<td>40-100</td>
<td>2</td>
</tr>
<tr>
<td>Flexed Elbow</td>
<td>Brachioradialis</td>
<td>25-100</td>
<td>1-3</td>
</tr>
<tr>
<td></td>
<td>Biceps</td>
<td>75-200</td>
<td>1-4</td>
</tr>
<tr>
<td></td>
<td>Brachialis</td>
<td>25-100</td>
<td>1-2</td>
</tr>
<tr>
<td>Pronated Forearm</td>
<td>Pronator quadratus</td>
<td>10-50</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Pronator teres</td>
<td>25-75</td>
<td>1-2</td>
</tr>
<tr>
<td>Thumb-in-Palm</td>
<td>Flexor pollicis longus</td>
<td>10-50</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Adductor pollicis</td>
<td>5-30</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Flexor pollicis brevis/</td>
<td>5-30</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Opponens pollicis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total dosing should not exceed 400 units per treatment session involving different muscles.

Initial dosing should begin at the lowest recommended dose for the specific indication and be cautiously titrated within recommended dose range for optimal patient outcome.

Median onset of effect is observed four days after injection. The maximum effect as an improvement of muscle tone is observed after approximately 4 weeks. The effect of each treatment generally lasts approximately 3 months; however, it may last significantly longer or shorter. The period between each treatment session is recommended to be at least 12 weeks.

**Administration**

The multiple point injection technique into target muscles with disperse innervation zones can reduce undesirable effects and, at the same time, may reach more intrafusal fibres.

**Blepharospasm**

Reconstituted XEOMIN® is injected using a suitable sterile needle (e.g. 27-30 gauge / 0.30-0.40 mm). Electromyographic guidance is not necessary.
XEOMIN® is injected into the medial and lateral orbicularis oculi muscle of the upper lid and the lateral orbicularis oculi muscle of the lower lid. Additional sites in the brow area, the lateral orbicularis oculi muscle and in the upper facial area may also be injected if spasms here interfere with vision.

Injections near the levator palpebrae superioris should be avoided to reduce the occurrence of ptosis. Diplopia may develop as a result of Botulinum neurotoxin type A diffusion into the obliquus oculi inferior. Avoiding medial injections into the lower lid may reduce this adverse reaction.

**Spasmodic torticollis**

In the management of spasmodic torticollis, XEOMIN® dosing must be tailored to the individual patient, based on the patient’s head and neck position, location of possible pain, muscle hypertrophy, patient’s body weight, and response to the injection. A suitable sterile needle (e.g. 25-30 gauge / 0.30-0.50 mm) is used for injections into superficial muscles, and an e.g. 22 gauge / 0.70 mm needle may be used for injections into deeper musculature. An injection volume of approximately 0.1 to 0.5 mL per injection site is recommended.

In the management of spasmodic torticollis, XEOMIN® is usually injected into the sternocleidomastoid, levator scapulae, scalenus, splenius capitis, and/or the trapezius muscle(s). This list is not exhaustive as any of the muscles responsible for controlling head position may be involved and therefore require treatment. If difficulties arise isolating single muscles, injections should be performed using electromyographic guidance. The muscle mass and the degree of hypertrophy or atrophy are factors to be taken into consideration when selecting the appropriate dose.

Multiple injection sites permit XEOMIN® more uniform coverage of the innervated areas of the dystonic muscle and are especially useful in larger muscles. The optimum number of injection sites is dependent upon the size of the muscle to be chemically denervated.

The sternocleidomastoid should not be injected bilaterally as there is an increased risk of adverse reactions (in particular dysphagia) when bilateral injections or doses in excess of 100 units are administered into this muscle.

**Post-stroke Spasticity of the Upper Limb**

Reconstituted XEOMIN® is injected using a suitable sterile needle (e.g. 26 gauge / 0.45 mm diameter / 37 mm length, for superficial muscles and a longer needle, e.g. 22 gauge / 0.7 mm diameter / 75 mm length, for deeper musculature). An injection volume of approximately 0.2 to 1 mL per injection site is recommended, but it can be exceeded to 1.5 mL in selected cases.

Localisation of the involved muscles with electromyographic guidance or nerve stimulation techniques may be necessary. Multiple injection sites may allow XEOMIN® to have more uniform contact with the innervation areas of the muscle and are especially useful when larger muscles are injected.
The exact dosage and number of injection sites should be tailored to the individual patient based on the size, number and location of muscles to be treated, the severity of spasticity, and the presence of local muscle weakness. Initial dosing should begin at the lowest recommended dose and be cautiously titrated within the recommended dose range for optimal patient outcome.

**Reconstitution**

This medicinal product must not be mixed with other medicinal products except those mentioned below.

**XEOMIN**® is reconstituted prior to use with sterile unpreserved sodium chloride 9 mg/mL (0.9%) solution for injection. Reconstitution and dilution should be performed in accordance with good clinical practice guidelines, particularly with respect to asepsis.

It is good practice to perform vial reconstitution and syringe preparation over plastic-lined paper towels to catch any spillage. An appropriate amount of solvent (Table 8) is drawn up into a syringe. A 20-27 gauge short bevel needle is recommended for reconstitution. The exposed portion of the rubber stopper of the vial is cleaned with alcohol (70%) prior to insertion of the needle. After vertical insertion of the needle through the rubber stopper the solvent is injected gently into the vial in order to avoid foam formation. The vial must be discarded, if the vacuum does not pull the solvent into the vial. Remove the syringe from the vial and mix XEOMIN® with the solvent by carefully swirling and inverting the vial – do not shake vigorously. Record the date and time of reconstitution on the vial.

If needed, the needle used for reconstitution should remain in the vial and the required amount of solution should be drawn up with a new sterile syringe suitable for injection.

Reconstituted XEOMIN® is a clear colourless solution free of particulate matter.

**XEOMIN**® should not be used if the reconstituted solution (prepared as above) has a cloudy appearance or contains floccular or particulate matter.
Table 8: Possible Dilutions of XEOMIN® in the Reconstituted Solution

<table>
<thead>
<tr>
<th>Solvent added (sodium chloride 9 mg/mL (0.9%) solution for injection)</th>
<th>Resulting dose in units per 0.1 mL</th>
<th>Resulting dose in units per 0.1 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25 mL</td>
<td>20.0 U</td>
<td>--</td>
</tr>
<tr>
<td>0.5 mL</td>
<td>10.0 U</td>
<td>20.0 U</td>
</tr>
<tr>
<td>1.0 mL</td>
<td>5.0 U</td>
<td>10.0 U</td>
</tr>
<tr>
<td>2.0 mL</td>
<td>2.5 U</td>
<td>5.0 U</td>
</tr>
<tr>
<td>4.0 mL</td>
<td>1.25 U</td>
<td>2.5 U</td>
</tr>
</tbody>
</table>

Any solution for injection that has been stored for more than 24 hours as well as any unused solution for injection should be discarded. For safe disposal of the reconstituted solution, see SPECIAL HANDLING INSTRUCTIONS.

OVERDOSAGE

The lethal amount of crystalline Botulinum toxin type A for a 70 kg human is calculated to be approximately 0.09 to 0.15 µg applied intravenously or intramuscularly, and 70 µg applied orally. A vial with 100 units XEOMIN® contains 0.6 ng Botulinum neurotoxin type A, i.e. less than 1/100 of the estimated human lethal dose following intravenous or intramuscular application. A vial with 50 units of XEOMIN® contains 0.3 ng Botulinum neurotoxin type A, i.e. less than 1/200 of the estimated human lethal dose following intravenous or intramuscular application.

Symptoms of Overdose

Overdose of XEOMIN® depends upon dose, site of injection and underlying tissue properties. Signs and symptoms of overdose are not apparent immediately post-injection. Increased doses may result in paralysis distant from the site of injection with a variety of symptoms. Symptoms may include general weakness, ptosis, diplopia, breathing difficulties, speech difficulties, paralysis of the respiratory muscles or swallowing difficulties which may result in aspiration pneumonia.

Measures in Cases of Overdose

Should accidental injection or oral ingestion occur, or overdose be suspected, the person should be medically monitored for up to several weeks for symptoms of excessive muscle weakness or muscle paralysis. Symptomatic treatment may be necessary. Respiratory support may be required if paralysis of the respiratory muscles occurs.

For management of a suspected drug overdose, contact your regional Poison Control Centre.
ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action
The mechanism of action of Botulinum neurotoxin type A is well characterized. It involves a 4 step process resulting in a reduction in muscular contractions. The 4 steps include binding, uptake within a vesicle, translocation into cytosol and proteolytic cleavage of SNAP 25.

The C-terminal end of the heavy chain of Botulinum neurotoxin type A binds to binding sites (ganglioside GT1b and the synaptic vesicle membrane protein SV2C) on presynaptic cholinergic axon terminals with very high specificity and affinity (picomolar range). The actual protein binding site of Botulinum neurotoxin type A has not yet been fully characterized.

After binding, the complete Botulinum neurotoxin type A molecule is taken up by endocytosis so that it resides in an endocytic vesicle in the cytosol of the nerve terminal. Translocation of the Botulinum neurotoxin type A light chain from the vesicle into the cytosol is then mediated by a 50 kD N-terminal domain of the heavy chain which undergoes a configuration change to form a transmembrane hydrophilic pore in the vesicle, through which the light chain, a zinc-dependent endopeptidase, protrudes into the cytosol. Translocation is detectable in vitro within 20 minutes of binding, and reaches a peak after 90 minutes.

After translocation into the nerve terminal cytosol, the light chain of the neurotoxin becomes proteolytically active and specifically cleaves a component (SNAP 25) of the vesicle fusion machinery, which is essential for the release of acetylcholine. By inhibiting acetylcholine release Botulinum neurotoxin type A reduces muscular contractions. The blockade of transmission at the neuromuscular junction leads to retraction of the endplate nerve terminals and subsequent loss of endplate organization.

Extensive compensatory sprouting by the affected terminal nerve membrane begins within 4 days, leading to the formation of temporary functional synapses and partial recovery of muscle function within approximately 28 days of treatment. Within approximately 2 months, the affected nerve terminals begin to recover their ability to release acetylcholine and the original endplate connections are progressively restored. Sprouting stops and the temporary synapses begin to lose their functionality. Within approximately 3 months, the original nerve endings recover full functionality, leading to the normalization of the original motor endplates. This induces retraction and regression of the sprouts and a complete functional repair of the original terminals.

In addition, cholinergic, autonomic, parasympathetic, and postganglionic sympathetic nerve synapses are also potential targets of therapeutic intervention, e.g. the intradermal application of Botulinum neurotoxin type A leads to denervation of eccrine glands. It is therefore conceivable that systematic autonomic side effects of local Botulinum neurotoxin type A injections may include dryness of the mouth and eyes and ocular accommodation difficulties.
**Pharmacodynamics**

The pharmacodynamics of locally injected Botulinum neurotoxin type A are well established, with dose-related muscle weakness resulting from the irreversible blockade of acetylcholine release from presynaptic vesicles.

The desired pharmacological effect of Botulinum neurotoxin type A relates to reduced muscle contraction in the target muscle, whereas undesirable effects appear to relate to the diffusion of toxin from the target muscle to adjacent muscles and/or nerves. Muscle relaxation generally occurs within 2 to 5 days after intramuscular injection, with an expected maximum effect after 2 weeks and a duration of effect for an average of 9 to 16 weeks.

The diffusion of Botulinum neurotoxin type A from intramuscular injection sites into surrounding tissue is dose-dependent. Limiting the dose of Botulinum neurotoxin type A in critical anatomical areas is therefore helpful in preventing complications (e.g. limiting dose administered to the orbicularis oculi muscle to prevent ptosis, or limiting the dose administered to the sternocleidomastoid muscle to prevent dysphagia in cervical dystonia). The multiple point injection technique into target muscles with disperse innervation zones (e.g., sternocleidomastoid muscle, orbicularis oculi muscle) can reduce undesirable effects in Botulinum neurotoxin type A-treated patients and, at the same time, may reach more intrafusal fibres.

Two pharmacodynamic studies were conducted with XEOMIN® (incobotulinumtoxinA) in healthy volunteers. The studies were active-control (onabotulinumtoxinA) studies conducted in a small foot muscle [extensor digitorum brevis (EDB)] model. Active control studies showed a reduction in compound muscle action potential (CMAP) in all subjects with similar effects between treatments. No significant difference was seen between preparations with respect to degree of paralysis, onset of paralysis, and duration of effect. In a dose-response study overall, a dose-response relationship was observed when the highest dose (32 unit) and the lowest dose (2 unit) groups were compared with similar effects for XEOMIN® (incobotulinumtoxinA) and the conventional Botulinum toxin type A preparation (onabotulinumtoxinA) observed in all dose groups. No local diffusion of either preparation was observed in adjacent muscles at tested doses.

**Pharmacokinetics**

Classic kinetic and distribution studies cannot be conducted with Botulinum neurotoxin type A because the active substance is applied in very small quantities (picograms per injection), and because it binds so rapidly and irreversibly to cholinergic nerve terminals.

Like many other proteins of its size, Botulinum neurotoxin type A has been shown to undergo retrograde axonal transport after intramuscular injection. Retrograde transsynaptic passage of active Botulinum neurotoxin type A into the central nervous system however has not been found. Proteolyzed Botulinum neurotoxin type A yields amino acids which will enter the normal physiological metabolic pathways, being recycled or catabolized, according to the needs of the cell.

**Duration of Effect**

See **DOSAGE AND ADMINISTRATION**.
STORAGE AND STABILITY

XEOMIN®, unreconstituted, is stored at room temperature (up to 25°C) and should not be used after the expiry date stated on the outer package.

Reconstituted solution: This product does not contain any antimicrobial preservatives and should ideally be used immediately after reconstitution. Reconstituted solution is stable for up to 24 hours at 2 to 8°C.

Do not freeze reconstituted XEOMIN®.

SPECIAL HANDLING INSTRUCTIONS

Procedure to follow for a safe disposal of vials, syringes and materials used:
Any unused vials, residual reconstituted solution in the vial and/or syringe should be inactivated by adding one of the following solutions: 70% ethanol, 50% isopropanol, diluted sodium hydroxide solution (0.1 N NaOH), or diluted sodium hypochlorite solution (at least 0.1% NaOCl).

Used vials, syringes, and materials should not be emptied and should be discarded into appropriate containers and disposed of in accordance with local requirements.

Recommendations should any incident occur during the handling of Botulinum toxin:
Any spills of the product must be wiped up: either using absorbent material impregnated with any of the above listed solutions in case of the powder, or with dry, absorbent material in case of reconstituted product.

The contaminated surfaces should be cleaned using absorbent material impregnated with any of the above listed solutions, then dried.

If a vial is broken, proceed as mentioned above by carefully collecting the pieces of broken glass and wiping up the product, avoiding any cuts to the skin.

If the product comes into contact with skin, rinse the affected area abundantly with water.

If product gets into the eyes, rinse thoroughly with plenty of water or with an ophthalmic eyewash solution.

If product comes into contact with a wound, cut or broken skin, rinse thoroughly with plenty of water and take the appropriate medical steps according to the dose injected.

DOSAGE FORMS, COMPOSITION AND PACKAGING
XEOMIN® is supplied as a sterile, white, preservative free powder for solution for injection (lyophilisate) packed in a vial of type 1 glass with a latex-free stopper (bromobutyl rubber) and tamper-proof seal (aluminum).
XEOMIN® is available in pack sizes of 1 (single unit pack), 2, 3 or 6 vials (multi-packs).

Each vial contains either 50 or 100 LD₅₀ units of incobotulinumtoxinA (*Clostridium Botulinum* Neurotoxin Type A (150 kD), free from complexing proteins) where one unit corresponds to the median lethal dose (LD₅₀) when the reconstituted product is injected intraperitoneally into mice under defined conditions, 4.7 mg of sucrose and 1.0 mg of human serum albumin. Prior to use XEOMIN® is reconstituted with commercially available 0.9 % physiological saline (not supplied in the pack) to form a clear, and colorless solution.

Due to differences in the LD₅₀ assay, these units are specific to XEOMIN® and are not interchangeable with other Botulinum toxin preparations.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: incobotulinumtoxinA

Chemical Name: Botulinum Toxin Type A (toxinum botulinicurm typum A).

Molecular Formula and Molecular Mass:

IncobotulinumtoxinA is synthesised by the anaerobic bacterium Clostridium botulinum as a single chain polypeptide (1,296 amino acid residues, molecular weight ~150 kD), which is subsequently split between residues 438 and 439 as well as between residues 448 and 449 by an endogenous protease during post-translational modification. A decapeptide (residue 439 to residue 448) is cleaved from the protein, resulting in a heavy chain, with a molecular weight of ~100 kD, and a light chain, with a molecular weight of ~50 kD. These separate chains are covalently linked via a disulphide bond. The light chain is associated with one zinc ion and functions as a zinc-dependent endopeptidase. The heavy chain comprises two functional domains: the N-terminal section is the translocation domain and the C-terminal section is the binding domain (Figure 1).
Structural Formula:

Figure 1: Structure of the 150 kD purified neurotoxin free from complexing proteins (incobotulinumtoxinA)

Physicochemical Properties:

XEOMIN® (incobotulinumtoxinA) is supplied as a sterile, white, preservative free powder for solution for injection (lyophilisate) packed under nitrogen in single-use glass vials. Each vial contains either 50 or 100 mouse LD$_{50}$ units of incobotulinumtoxinA (Clostridium Botulinum Neurotoxin Type A (150 kD), free from complexing proteins), 4.7 mg of sucrose and 1.0 mg of human serum albumin. Prior to use XEOMIN® is reconstituted with commercially available 0.9 % physiological saline (not supplied in the pack) to form a clear, and colorless solution. The size of the vials allows different concentrations (i.e. doses) to be prepared.

Product Characteristics:

XEOMIN® is a formulation of incobotulinumtoxinA. It is produced by the anaerobic bacterial fermentation process from the Hall strain of Clostridium botulinum as a single chain polypeptide with a molecular weight of approximately 150 kD. The neurotoxin is a part of a high molecular weight complex (Mr = 900 kD) consisting of at least five additional proteins (= complexing proteins). During the unique manufacturing process of the drug substance the neurotoxin is taken through a number of purification steps, which separate the complexing proteins from the neurotoxin. It consists of the purified neurotoxin which has been separated from complexing proteins (hemagglutinins and a non-toxic non-hemagglutinating protein) during production.
**CLINICAL TRIALS**

**Study demographics and trial design**
The safety and efficacy of XEOMIN® were assessed in five randomized double-blind, parallel group, controlled multicenter trials. Study demographics and trial design are summarized in Table 9.

**Table 9: Summary of patient demographics for clinical trials on safety and efficacy of XEOMIN®**

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design / Indication</th>
<th>Dosage and route of administration</th>
<th>Study subjects (n=number)</th>
<th>Mean age in years (Range)</th>
<th>No. male (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-CD</td>
<td>Randomised double-blind active-controlled parallel group multicentre trial to test non-inferiority / Cervical dystonia</td>
<td>XEOMIN®: 70 to 300 U Active Comparator: 70 to 300 U intramuscular injection at baseline</td>
<td>n=463 ITT n=420 TPP</td>
<td>XEOMIN®: 50.3 (18 – 74)</td>
<td>XEOMIN®: 87 (37.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>900 kD Active Comparator: 49.2 (20 – 75)</td>
<td>900 kD Active Comparator: 90 (38.8)</td>
</tr>
<tr>
<td>2-CD</td>
<td>Randomized double-blind placebo-controlled parallel group multicentre trial with a Double-Blind Extension Period (DBEX) / Cervical dystonia</td>
<td>Main Period: XEOMIN® 120 U or 240 U or placebo intramuscular injection at baseline</td>
<td>Main Period: n=233 ITT n=215 TPP</td>
<td>Main Period: XEOMIN® 120 U: 52.8 (18-73)</td>
<td>Main Period: XEOMIN® 120 U: 27 (34.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>240 U: 53.2 (22-75)</td>
<td>240 U: 27 (33.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Placebo: 52.4 (30-79)</td>
<td>Placebo: 25 (33.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DBEX Period: 120 U or 240 U; up to 5 intramuscular injections within 48 weeks</td>
<td>DBEX Period:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>XEOMIN® 120 U: 53.6 (24-74)</td>
<td>XEOMIN® 120 U: 34 (33.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>240 U: 52.4 (18-79)</td>
<td>240 U: 42 (37.8)</td>
</tr>
<tr>
<td>1-BLEPH</td>
<td>Randomised double-blind active-controlled parallel group multicentre trial to test non-</td>
<td>XEOMIN®: ≤35 U per eye Active</td>
<td>n=300 ITT n=256 TPP</td>
<td>XEOMIN®: 63.9 (37 – 87)</td>
<td>XEOMIN®: 32 (21.6)</td>
</tr>
<tr>
<td>Study #</td>
<td>Trial design / Indication</td>
<td>Dosage and route of administration</td>
<td>Study subjects (n=number)</td>
<td>Mean age in years (Range)</td>
<td>No. male (%)</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------</td>
<td>------------------------------------</td>
<td>--------------------------</td>
<td>--------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td></td>
<td>inferiority / Blepharospasm</td>
<td>Comparator: ≤35 U per eye intramuscular injection at baseline</td>
<td>Double-blind Period: XEOMIN®: ≤50 U per eye or placebo intramuscular injection at baseline</td>
<td>Double-blind Period: XEOMIN®: 61.5 (25–81)</td>
<td>Active Comparator: 900 kD 50 (32.9)</td>
</tr>
<tr>
<td>2-BLEPH</td>
<td>Randomized double-blind placebo-controlled, parallel group multicenter trial with an Open-Label Extension (OLEX) Period / Blepharospasm</td>
<td>Double-blind Period: XEOMIN®: ≤50 U per eye or placebo intramuscular injection at baseline</td>
<td>OLEX Period: XEOMIN®: ≤50 U per eye; up to 5 intramuscular injections within 48 weeks</td>
<td>OLEX Period: n = 102 ITT n = 76 TPP</td>
<td>Placebo: 62.6 (46–79)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OLEX Period: n = 102 ITT n = 76 TPP</td>
<td>OLEX Period: n = 102 ITT n = 76 TPP</td>
<td>Placebo: 62.2 (22–79)</td>
<td>Placebo: 12 (35.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OLEX Period: n = 102 ITT n = 76 TPP</td>
<td>OLEX Period: n = 102 ITT n = 76 TPP</td>
<td>OLEX Period: 36 (35.3)</td>
<td>Double-blind Period: XEOMIN®: 26 (34.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OLEX Period: n = 102 ITT n = 76 TPP</td>
<td>OLEX Period: n = 102 ITT n = 76 TPP</td>
<td>OLEX Period: 36 (35.3)</td>
<td>Placebo: 12 (35.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OLEX Period: n = 148 ITT n = 140 TPP</td>
<td>OLEX Period: n = 148 ITT n = 140 TPP</td>
<td>Placebo: 53.3 (23 – 79)</td>
<td>Placebo: 50 (66.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OLEX Period: n = 148 ITT n = 140 TPP</td>
<td>OLEX Period: n = 148 ITT n = 140 TPP</td>
<td>OLEX Period: 93 (64.1)</td>
<td>Double-blind Period: XEOMIN®: 45 (61.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OLEX Period: n = 148 ITT n = 140 TPP</td>
<td>OLEX Period: n = 148 ITT n = 140 TPP</td>
<td>OLEX Period: 93 (64.1)</td>
<td>Placebo: 50 (66.7)</td>
</tr>
</tbody>
</table>

ITT: Intent to treat; TPP: Treated per protocol
Study results

Study 1 - Cervical Dystonia

The aim of this study was to show non-inferiority of XEOMIN® compared to Active Comparator 1 in terms of safety and efficacy in patients with cervical dystonia. Eligible patients had a Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) – severity score ≥ 10, required injectable treatment of their cervical dystonia and had received at least two injections of Active Comparator 1 (onabotulinumtoxinA) with stable therapeutic response.

Both XEOMIN® and Active Comparator 1 (onabotulinumtoxinA) induced significant reductions in TWSTRS - Severity score from baseline to Week 4. This change in primary efficacy variable was statistically significant and demonstrated the efficacy of both treatments (p<0.0001 in both groups, ANCOVA for mean scores at control visit vs. baseline). The least square mean difference between the groups in the primary efficacy variable was -0.33 points. The upper 95% confidence limits of this difference between the two groups in the treatment induced changes in the TWSTRS - Severity score were lower than the pre-defined difference of Δ=1.3 points in all ANCOVA models of adjustments for relevant covariates (TPP population: final model 0.38). Thus, non-inferiority of XEOMIN® compared to Active Comparator 1 (onabotulinumtoxinA) (Table 10) was demonstrated.

Table 10: Change from Baseline in TWSTRS - Severity Score – TPP Population (Study 1-CD)

<table>
<thead>
<tr>
<th></th>
<th>XEOMIN® (N=213)</th>
<th>Active Comparator 1 (N=207)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean TWSTRS - Severity score (±SD)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>17.8 (±3.5)</td>
<td>17.7 (±3.7)</td>
</tr>
<tr>
<td>Control Visit (Week 4)</td>
<td>11.1 (±4.8)</td>
<td>11.4 (±4.8)</td>
</tr>
<tr>
<td><strong>Least squares mean change from baseline to control visit</strong></td>
<td>-6.95</td>
<td>-6.62</td>
</tr>
<tr>
<td><strong>Treatment difference (XEOMIN® – conventional preparation with 95% CI)</strong></td>
<td>p&lt;0.0001</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>-0.33</td>
<td>[−1.05 – 0.38]</td>
</tr>
</tbody>
</table>

Secondary efficacy variables confirmed the results of the primary endpoint. TWSTRS - Severity score was also significantly reduced at the final visit (up to 16 weeks) for both XEOMIN® and Active Comparator 1 (onabotulinumtoxinA), with no significant differences between the groups. For the TWSTRS factorial subscore, there were similar changes from baseline to control visit with XEOMIN® and Active Comparator 1 (onabotulinumtoxinA) for factors 1 (rotation, duration, motion + time), 2 (laterocollis + shoulder elevation/anterior displacement) and 3 (lateral shift + sensory tricks). For factor 4 (retrocollis/anterocollis and sagittal shift), a significant difference between the two groups in favour of XEOMIN® was observed (p=0.0223, ANCOVA). Both XEOMIN® and Active Comparator 1 (onabotulinumtoxinA) significantly reduced TWSTRS - pain subscore and Visual Analogue Scale (VAS) score for pain from baseline to control and to final visit with no significant difference between treatment groups.
Patient and investigator global assessments of efficacy were favourable for both XEOMIN® and Active Comparator 1 (onabotulinumtoxinA), with no significant differences between treatments. Analyses for the ITT population were in keeping with those for the TPP population. There was no significant difference in onset of action, duration of effect or waning of effect between the two treatment groups.

**Study 2 - Cervical Dystonia**

**Main Period**
Study 2-CD investigated the efficacy and safety of two XEOMIN® doses (120 U and 240 U) compared to placebo in the treatment of cervical dystonia. Patients (N=233) were randomized (1:1:1) to receive a single dose of XEOMIN® 240 U (n=81), 120 U (n=78) or placebo (n=74). Both pre-treated and treatment-naïve (40%) patients confirmed with clinical diagnosis of cervical dystonia (i.e. spasmodic torticollis) having TWSTRS scores: Total ≥20, Severity ≥10, Disability ≥3, and Pain score ≥1, were randomized. Following a single IM injection, patients were given a primary assessment at Week 4 and were followed for up to 20 weeks until a new injection was required. Patients could then continue to the extension phase of the study starting at Week 8 or as necessary through Week 20.

The primary efficacy variable, the change in TWSTRS-Total score from baseline to Week 4, was significantly greater in the XEOMIN® groups, compared with the placebo group (p<0.001). The descriptive mean changes (±standard deviation [SD]) in TWSTRS-Total score from baseline to Week 4 in the 240 U, 120 U, and placebo groups were -10.9 (±11.7), -9.9 (±10.4) and -2.2 (±7.3) points, respectively. The least square mean difference between the change in each XEOMIN® group and placebo was highly statistically significant (p<0.001; ANCOVA) and clinically meaningful: -9.0 points for 240 U vs. placebo, and -7.5 points for 120 U vs. placebo (Table 11). There was no statistically significant or clinically meaningful difference between the 240 U and 120 U dose groups.
Table 11: Change from Baseline in TWSTRS-Total Score – ITT Population (Study 2-CD)

<table>
<thead>
<tr>
<th></th>
<th>XEOMIN® (120 U) (N=81)</th>
<th>XEOMIN® (240 U) (N=78)</th>
<th>Placebo (N=74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean change from baseline to Visit 3 (Week 4)</td>
<td>-9.9 (±10.4)</td>
<td>-10.9 (±9.2)</td>
<td>-2.2 (±7.3)</td>
</tr>
<tr>
<td>Least squares [LS] mean difference between treatments (XEOMIN® - placebo with 95% CI), p-value</td>
<td>(-10.4, -4.6) p&lt;0.001</td>
<td>(-12.0, -5.9) p&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

LS mean differences given in the table are derived from an ANCOVA model with the following covariates: gender, age group, pre-treatment status, baseline TWSTRS-total score, and pooled center.

**Double-Blind Extension Period**
The Extension Period of Study 2-CD consisted of a 48-week double-blind, repeated dose, flexible interval extension period followed by a safety observation period of up to 20 weeks (48-69 weeks total study duration). A total of 214, 191, 168, 139 and 90 subjects received injection in cycles 1, 2, 3, 4 and 5, respectively. Patients received up to five injections of ≤4.8 mL 120 U or 240 U XEOMIN® at flexible injection intervals of at least six weeks, the timing based on the individual patient’s clinical needs (a patient-initiated request followed by clinical confirmation of a TWSTRS-Total score ≥20 points). The safety profile in patients requiring injections at shorter intervals (≤12 weeks) compared with those requiring treatment at longer intervals (>12 weeks) was similar. None of the patients who were naïve to Botulinum neurotoxin (n=62) developed neutralizing antibodies following treatment with XEOMIN®.

**Study 1 - Blepharospasm**
The aim of Study 1-BLEPH was to show non-inferiority of XEOMIN® compared to Active Comparator 1 (onabotulinumtoxinA) in patients with blepharospasm. Patients with a confirmed clinical diagnosis of blepharospasm who had been previously successfully treated with Active Comparator 1 (onabotulinumtoxinA) in at least 2 consecutive sessions and who had a consistent therapeutic response were enrolled.

The primary efficacy variable measured the change from baseline (day 0) in the mean Jankovic Rating Scale (JRS) sum score at the control visit (day 21±1). Both XEOMIN® and Active Comparator 1 (onabotulinumtoxinA) induced significant reductions in JRS from baseline by day 21 (p<0.0001, ANCOVA). XEOMIN® can be considered equivalent to Active Comparator 1 (onabotulinumtoxinA) with respect to efficacy since the pre-defined criteria for non-inferiority were met (Table 12). By final visit (up to 16 weeks), mean JRS scores remained significantly below baseline value in both groups, although the effect size was smaller than at control visit.
Table 12: Change from Baseline in JRS - TPP Population (Study 1-BLEPH)

<table>
<thead>
<tr>
<th></th>
<th>XEOMIN® (N=129)</th>
<th>Active Comparator 1 (N=127)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean JRS (±SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At baseline</td>
<td>5.3 (±1.5)</td>
<td>5.4 (±1.5)</td>
</tr>
<tr>
<td>At control visit (3 weeks)</td>
<td>2.5 (±2.0)</td>
<td>2.8 (±2.1)</td>
</tr>
<tr>
<td>Least squares mean change</td>
<td>-2.9</td>
<td>-2.7</td>
</tr>
<tr>
<td>from baseline to control</td>
<td>p&lt;0.0001</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td>visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment difference</td>
<td>-0.23</td>
<td>-0.23</td>
</tr>
<tr>
<td>(XEOMIN® - onabotulinumtoxinA with 95% CI)</td>
<td>(-0.68,0.22)</td>
<td></td>
</tr>
</tbody>
</table>

Secondary efficacy variables confirmed the results of the primary efficacy endpoint. Significant reductions were observed from baseline in the Blepharospasm Disability Index (BSDI) to control visit and final visit for both XEOMIN® (-0.83; 95% CI: -0.94, -0.73 and -0.41; 95% CI: -0.54, -0.29 respectively) and Active Comparator 1 (onabotulinumtoxinA) (-0.83; 95% CI: -0.93, -0.72 and -0.26; 95% CI: -0.38, -0.13 respectively) (p<0.0001), with no significant difference between the two treatment groups. Patients evaluation of global response (on a scale -4 [‘very marked worsening’] to +4 [‘complete abolishment of all signs and symptoms’]) was significantly improved in both groups at control and final visit compared with baseline, again with no significant differences between XEOMIN® (2.2; SD±1.6 and 2.2; SD±1.4 respectively) and Active Comparator 1 (onabotulinumtoxinA) (1.9; SD±1.4 and 2.0; SD±1.4 respectively). Analyses for the ITT population were congruent with those for the TPP population, except for a significant difference between the two treatment means for BSDI (p<0.01) at final visit, in favour of XEOMIN®. There was no significant difference between XEOMIN® and Active Comparator 1 (onabotulinumtoxinA) in onset of action (7.7±SD12.9 days and 9.2±SD18.6 days respectively; p=0.91), duration of effect (97.7±SD25.0 days and 97.9±SD28.5 days respectively; p=0.86) or waning of effect (10.6±SD3.9 weeks and 10.3±SD4.2 weeks respectively; p=0.58).

**Study 2 – Blepharospasm**

**Double-Blind Period**

Study 2-BLEPH investigated the efficacy and safety of XEOMIN® after a single IM injection (at a mean dose of 33 U, range from 10-50 U per eye) compared to placebo in patients with blepharospasm (clinical diagnosis of bilateral blepharospasm and JRS-Severity subscore of ≥2 at baseline) who were previously successfully treated with onabotulinumtoxinA and who had a consistent therapeutic response in at least 2 consecutive sessions. Patients were randomized to receive a single administration of XEOMIN® (n=75) or placebo (n=34) and were followed for 6 to 20 weeks until a new injection was required; patients could then continue to the extension phase of the study.

The primary efficacy variable was the change from baseline to Week 6 of the JRS-Severity subscore. The mean (±SD) JRS-Severity subscore decreased from baseline to Week 6 in the XEOMIN® group (-0.83±1.18 points) and increased in the placebo group (0.21±0.91 points).
The difference between treatments of -1.0 points (95% confidence interval [CI]): (-1.4, -0.5) was statistically significant (p<0.001).

**Table 13: Change from Baseline in JRS Severity Subscore – ITT Population (Study 2-BLPH)**

<table>
<thead>
<tr>
<th></th>
<th>XEOMIN® (N=75)</th>
<th>Placebo (N=34)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean JRS severity subscore (±SD)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At baseline</td>
<td>3.12 (±0.73)</td>
<td>2.94 (±0.81)</td>
</tr>
<tr>
<td>At Visit 4 (Week 6)</td>
<td>2.29 (±1.19)</td>
<td>3.15 (±0.99)</td>
</tr>
<tr>
<td>Mean change from baseline to Visit 4 (Week 6)</td>
<td>-0.83 (±1.18)</td>
<td>0.21 (±0.91)</td>
</tr>
<tr>
<td>Least squares [LS] mean difference* between treatments (XEOMIN® - placebo with 95% CI)</td>
<td>-1.0 (-1.4, -0.5)</td>
<td>p&lt;0.001</td>
</tr>
</tbody>
</table>

*LS mean difference is derived from an ANCOVA model with the following covariates: gender, age group, baseline JRS severity subscore, and pooled center.

**Open-Label Extension (OLEX) Period**

The OLEX Period evaluated the long-term efficacy and safety of XEOMIN® treatments. Patients who previously participated in the placebo-controlled study entered the OLEX Period and were treated with up to five injections of XEOMIN® over a 48-week treatment period with a minimum interval between two injections of at least six weeks. Injection intervals were flexible and timing based on the individual patient’s clinical needs (a patient-initiated request followed by clinical confirmation of a JRS severity subscore ≥2). A total of 102, 93, 87, 81 and 56 subjects received injection in cycles 1, 2, 3, 4 and 5, respectively, administered at mean doses of approximately 65 to 73 U in both eyes (maximum 50 U per eye). XEOMIN® was effective and well tolerated during 1-year repeated treatments in patients with blepharospasm.

**Study 1 – Post-stroke Spasticity of the Upper Limb**

**Double-Blind Period**

Study 1-PSSUL (double-blind period) investigated the efficacy and safety of XEOMIN® compared to placebo in the treatment of post-stroke spasticity of the upper limb. Naïve (73.6%) and pre-treated patients with a confirmed diagnosis of post-stroke spasticity of the upper limb were randomized to either placebo or XEOMIN®. All patients had clinical patterns for flexed wrist and clenched fist as well as an Ashworth score of ≥2 (i.e., marked increase in tone). Besides these, flexed elbow, pronated forearm, and thumb-in-palm had to be treated if the Ashworth score was ≥2 and could also be treated if the Ashworth score was at least 1.

Spasticity-related efficacy evaluations were based on the Ashworth Scale assessments for the treated muscle groups: flexors of elbow, wrist, fingers, thumb as well as forearm pronators. The primary outcome measure of efficacy was a responder analysis at Week 4 for patients with at least a 1-point improvement (reduction) from baseline in the Ashworth score for wrist flexors. Various additional definitions of response in flexed wrist and the other clinical patterns were
assessed as secondary efficacy variables. In addition, the extent of functional impairment was measured by the Disability Assessment Scale (DAS).

In the XEOMIN® group, 50 patients (68.5%) were treatment responders compared to 28 patients (37.3%) in the placebo group. There was a statistically significant and clinically relevant higher chance that a patient treated with XEOMIN® had at least 1-point improvement in the Ashworth Scale score for wrist flexors compared with placebo (Odds Ratio XEOMIN®: Placebo for all covariates = 3.97; 95% CI: 1.90, 8.30, p<0.001).

The results of the secondary efficacy parameters provided further evidence for a statistically significant and clinically relevant superiority of XEOMIN® compared to placebo. These included a 2-point improvement in the Ashworth Scale for wrist flexors at Week 4; (Odds ratio [OR] XEOMIN®/placebo = 6.95; 95% CI: 1.69 to 28.53; p=0.007 and 1-point improvement at all post-baseline visits). Overall, higher responder rates (1-point improvement on the Ashworth Scale score from baseline) were seen in the XEOMIN® treatment group for all visits and for all groups of muscles, compared to the placebo group. The proportion of responders in the XEOMIN® treatment group was ≥50% in all muscle groups treated for at least 8 weeks. More patients experienced improvements in Ashworth Scale in the XEOMIN® treatment group at all post-baseline visits compared to the placebo group. A graphic demonstration of responder rates at Week 4 in various muscle groups treated is provided in Figure 2.

Figure 2: Responder Rates (≥1-point Improvement) after Four Weeks for each Muscle Group (Observed Cases for the Clinical Pattern) – ITT Population (Study 1-PSSUL)
To investigate the effect of treatment on functional impairment, assessments on the Disability Assessment Scale [DAS] were performed. Statistically significant differences were observed between treatment groups for the principal function target chosen by the investigator and patient together at screening for Weeks 2, 4, 8 and 12; p≤0.005 (Table 14).

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Week 2</th>
<th>Week 4</th>
<th>Week 8</th>
<th>Week 12</th>
<th>Final Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>XEOMIN® (n = 73) Improvement (%)</td>
<td>39.8</td>
<td>45.2</td>
<td>45.2</td>
<td>38.4</td>
<td>30.1</td>
</tr>
<tr>
<td>Placebo ( n= 75) Improvement (%)</td>
<td>12.0</td>
<td>21.3</td>
<td>21.3</td>
<td>16.0</td>
<td>20.0</td>
</tr>
<tr>
<td>Between treatments comparisons p-value</td>
<td>&lt;0.001</td>
<td>0.002</td>
<td>0.005</td>
<td>0.005</td>
<td>0.214</td>
</tr>
</tbody>
</table>

1 Percentage of patients with an improvement of at least 1 point on the DAS compared to baseline.
2 Wilcoxon two-sample test p-values (zero change imputation) for change from baseline.

Statistically significant differences were observed between treatment groups for all therapeutic domains (ITT population) for XEOMIN® compared to placebo: hygiene (up to Week 8: 32.8% vs. 17.3% respectively, p=0.036), dressing (Week 2: 37.4% vs. 6.7%, p=0.003); limb position (up to Week 8: 41.1% vs. 14.6% respectively, p=0.003); and pain (up to Week 4: 28.8% vs. 8.0%, respectively, p=0.042). In the Carer Burden Scale, used to investigate the impact of treatment on carer burden, statistically significant superiority of the treatment with XEOMIN® compared to placebo was observed at Week 4 for “putting the affected arm through the sleeve” (p=0.021) and for “cleaning the palm of affected hand” (p=0.028; ITT population). No statistically significant differences from placebo were seen for other items of the Carer Burden Scale (cutting the fingernails of the affected hand, cleaning the armpit of the affected arm, applying a splint on the affected arm) at any of the time points examined (Week 4, Week 12 and final visit).

A significantly shorter median time to onset of treatment effect (4 days versus 20 days; p<0.001) was observed in the XEOMIN® group relative to placebo. The median duration of the treatment effect observed for the XEOMIN® group was 12.4 weeks (87 days) compared to 12 weeks (84 days) for the placebo patients.

XEOMIN® was effective in the treatment of post-stroke spasticity of the upper limb. As shown by the evaluation of odds ratios, XEOMIN® was effective in reducing muscle tone in wrist, finger, elbow, and thumb flexors as well as in forearm pronators. Treatment with XEOMIN® led to significant improvements in functional impairment and in some relevant tasks in caregiver burden.

**Open-Label Extension (OLEX) Period**

This open-label extension (OLEX) period of the completed double-blind, placebo-controlled clinical trial evaluated the long-term efficacy and safety of XEOMIN® treatments in PSSUL.
Patients who previously participated in the placebo-controlled study entered the OLEX Period and were treated with up to five injection intervals over 1 year (48 to 69 weeks) with a minimum interval between two injections of at least twelve weeks. Evaluations were performed based on the Ashworth Scale, Disability Assessment Scale (DAS), global assessments, and standard safety testing.

Out of 148 patients who participated in the double-blind period of the study, 145 entered the OLEX Period and 120 patients completed the 1-year trial period. Upper limb muscle groups were treated as clinically indicated (median dose = 400 units; min, max = 95, 500 units). The majority of patients (N = 129) have received up to four injection intervals. Effects seen on the Ashworth Scale score were highly statistically significant (p<0.0001; Wilcoxon signed rank test) during all four injection intervals and in all upper limb muscle groups treated (flexors of elbow, thumb, wrist and fingers as well as forearm pronators). XEOMIN® was effective in reducing functional impairment as shown on the DAS (principal therapeutic target and therapeutic domains of hygiene, dressing, limb position, and pain). Efficacy was assessed as very good or good by the majority of investigators, patients and caregivers (range: 56.3% to 85.3%).

None of the patients naïve to Botulinum neurotoxin (n=109) developed neutralizing antibodies following exposure in up to six treatment sessions, and a maximum dose of 400 U of XEOMIN® per injection, over a 61-week period.

In conclusion, XEOMIN® was effective and well tolerated during 1-year repeated treatments with a median dose of 400 units in patients with post-stroke spasticity of the upper limb. Optimal patient benefit is achieved by tailoring the targeted muscles, dosing units, and dosing interval according to the individual patient’s clinical needs at time of injection.

DETAILED PHARMACOLOGY

Mechanism of Action
See ACTION AND CLINICAL PHARMACOLOGY.

Human Pharmacodynamics
The desired pharmacological effect of Botulinum neurotoxin type A relates to reduced muscle contraction in the target muscle, whereas undesirable effects appear to relate to the diffusion of toxin from the target muscle to adjacent muscles and/or nerves. Muscle relaxation generally occurs within 2 to 5 days after intramuscular injection, with an expected maximum effect after 2 weeks and a duration of effect for an average of 9 to 16 weeks.

Two pharmacodynamic studies were conducted with incobotulinumtoxinA in healthy volunteers.

An active controlled study was conducted in 14 healthy male volunteers to compare the effect of incobotulinumtoxinA versus onabotulinumtoxinA on compound muscle action potential (CMAP) in a small foot muscle. Volunteers received intramuscular injections of 4 units of each preparation into the extensor digitorum brevis (EDB) of opposite feet. Measurements of CMAP were obtained by surface electromyography (EMG) after supramaximal electrical stimulation of
the peroneal nerve at regular intervals up to 90 days after treatment. The primary efficacy variable was the change from baseline in maximal CMAP.

Both incobotulinumtoxinA and onabotulinumtoxinA induced a reduction in CMAP in all subjects with no significant differences seen between the preparations with respect to degree of paralysis, onset of paralysis and duration of effect. Both were well tolerated, with no adverse events reported. The study confirmed that locally injected incobotulinumtoxinA is at least as effective as onabotulinumtoxinA at tested equal doses.

Another study was conducted in 32 healthy male volunteers to investigate the dose-response relationship, diffusion into the adjacent muscles, and duration of paralytic effect caused by incobotulinumtoxinA in the EDB model.

Volunteers were injected with a dose of 2, 4, 16, or 32 units of incobotulinumtoxinA in the EDB muscle of one foot, as randomly assigned. The same dose of onabotulinumtoxinA was injected in the contralateral EDB muscle. The primary efficacy endpoint was CMAP M-wave amplitude reduction (CAmR (%)) relative to baseline obtained in the EDB muscle at Week 4 for incobotulinumtoxinA. All dose groups showed a statistically significant EDB CAmR (%) at Week 4 compared to baseline. In the 32-unit dose group, the effect in the EDB CAmR (%) was higher compared to the other dose groups.

The systemic diffusion effects of the two products were compared by calculating within-subject differences of the ADQ CAmRs (%) and AH CAmRs (%) at Week 4. An effect was defined as a CAmR (%) decrease to < 80% of the baseline value and diffusion into adjacent ADQ and AH muscles, as indicated by the mean values of the CAmR (%) in these muscles observed over all dose groups. No systemic diffusion of incobotulinumtoxinA and onabotulinumtoxinA was observed in adjacent muscles at tested equal doses.

**Human Pharmacokinetics**

No specific pharmacokinetic studies have been performed with incobotulinumtoxinA. As Botulinum neurotoxin type A is administered in very small quantities (picograms per injection) and binds so avidly and irreversibly to cholinergic terminals, classic kinetic and distribution studies are not feasible in humans. (See ACTION AND CLINICAL PHARMACOLOGY - Pharmacokinetics).

**Animal Pharmacodynamics**

The paralytic activity of incobotulinumtoxinA and Botulinum Neurotoxin Type A-complex (Active Comparators 1 (onabotulinumtoxinA) and 2 (abobotulinumtoxinA)) was assessed in the mouse regional paralysis test after 3 repeated injections at 6 and 13 week intervals. Doses administered were approximately 32 LDU/kg for Active Comparator 1 and incobotulinumtoxinA and 72 LDU/kg for Active Comparator 2. Active Comparator 1 and incobotulinumtoxinA were equipotent in terms of mean paralysis score and animal days with severe paralysis. Degree and duration of paralysis were dose-dependent and were more marked after the second and third injections. The maximal paralytic effect was reached within days after the injections with all three preparations.
In another study, time course of paralysis and paralytic activity were almost comparable between Active Comparator 1 and incobotulinumtoxinA with maximum EMG activity inhibition one or two weeks after treatment in the Cynomolgus monkey. Recovery of the muscle activity began on average 9 weeks after treatment with full recovery achieved at study week 37.

Effects of incobotulinumtoxinA, onabotulinumtoxinA and abobotulinumtoxinA on motility were assessed in an acute intravenous toxicity study in mice at doses up to 68 LDU/kg. A significant dose dependent reduction in motility parameters was observed starting at 20 LDU/kg showing no differences between forms of Botulinum toxin type A. The NOAEL for motility parameters in mice after a single intravenous injection was 9 LDU/kg.

The *in vitro* inhibition of rapidly-activating delayed rectifier potassium currents (I\textsubscript{Kr}) by incobotulinumtoxinA was tested in Chinese Hamster Ovary cells stably expressing ether-à-go-go-related gene (hERG) product. At a concentration of 10,000 LDU/mL, there was no effect on tail currents at -20 mV. The tested concentration exceeds the maximum achievable concentration in human blood by a factor of at least 10,000 indicating that negative interactions with hERG channels in humans is extremely unlikely.

ECG parameters were studied in Cynomolgus monkeys after a single intramuscular administration of 16 LDU/kg incobotulinumtoxinA. There appeared to be no potential deleterious effect on the atrioventricular and intraventricular conduction velocity and ventricular repolarization.

A study of denervated muscle recovery in rats injected intramuscularly with incobotulinumtoxinA at doses up to 16 LDU/kg at weekly intervals showed full functional muscle recovery 26 weeks after the last injection, although histological recovery of muscle atrophy was not completed.

Intramuscular repeat dose studies of 13-39 weeks in Cynomolgus monkeys examined effects of doses up to 12 and 16 LDU/kg on cardiovascular function. The absence of cardiovascular effects was confirmed in all studies at all doses.

A study in the conscious rat after administration of up to 32 LDU/kg of incobotulinumtoxinA demonstrated no effect on intestinal transit 4 days after injection.

**Animal Pharmacokinetics**

The direct pharmacokinetic measurement of the absorption and bioavailability of incobotulinumtoxinA is not feasible because of its very low and thus undetectable effective tissue concentrations. However, the oral bioavailability can be estimated indirectly by comparing the potency of the drug substance after oral administration and the potency of the drug product after intravenous injection.

Single oral doses of incobotulinumtoxinA of up to 10,000 LDU did not produce mortality or clinical signs in male mice; a dose of 100,000 LDU produced 40% mortality. The intravenous LD\textsubscript{50} is approximately 50 LDU/kg corresponding to 1 LDU per animal. Based on the ratio of the intravenous to the oral approximative LD\textsubscript{50}, the oral bioavailability of incobotulinumtoxinA in mice is therefore 1:100,000 or 0.001%. 

XEOMIN® - Product Monograph  Page 40 of 50
In the literature, animal studies of tissue distribution using radiolabeled neurotoxin have shown that Botulinum toxin type A-complex remains concentrated at the intramuscular site for some time, with diffusion into tissues over distances of up to 5 cm depending on the volume injected. Furthermore, retrograde transport of Botulinum toxin type A-complex was observed in animals. However, no intact neurotoxin has been detected in the spinal cord, nor has biological activity of neurotoxin been found within the central nervous system after ventral root or intramuscular injection. Due to its molecular weight, there is no passage of the actual neurotoxin molecule into the CNS via the blood-brain barrier. After systemic absorption, Botulinum toxin type A-complex, like all protein fragments, is rapidly metabolized by proteases and the molecular components are recycled through normal metabolic pathways.

**TOXICOLOGY**

**Single-Dose Toxicity**

Single dose toxicity studies have been conducted with incobotulinumtoxinA in mice and rats by the intravenous, intraperitoneal, intramuscular and/or oral routes. A key finding of the acute toxicity studies is that incobotulinumtoxinA is practically non-toxic by oral administration. The oral LD50 is about 5 orders of magnitude higher than the intravenous and intraperitoneal LD50. When compared to Botulinum Neurotoxin Type A-complex the oral LD50 values for incobotulinumtoxinA in rats were about 60 times higher (55,300 LDU/kg versus approximately 3,200,000 LDU/kg, respectively).

A dose of 5 LDU/kg is considered the NOAEL for a single intramuscular administration of XEOMIN® (incobotulinumtoxinA) in mice.

**Repeat-Dose Toxicity**

Repeat dose toxicity studies were conducted in mice, rabbits and monkeys by the intended clinical intramuscular route of administration.

A 28-week repeat-dose study was conducted in mice with intramuscular injection three times at 6 and 13 week intervals at doses of up to 32 LDU/kg/administration for incobotulinumtoxinA and Active Comparator 1, and doses up to 78 LDU/kg/administration for Active Comparator 2. Active Comparator 1 and incobotulinumtoxinA were comparable in paralytic effect and in toxicity (in terms of weight loss per LDU). The NOAEL for incobotulinumtoxinA in this study was <13 LDU/kg.

A repeat-dose study (3 intramuscular injections at 14 day intervals) was conducted in rabbits involving 3 biweekly doses of incobotulinumtoxinA from 2.5 to 40 LDU/kg. Mortality was seen at 5 LDU/kg and higher. No marked local reactions and no treatment-related lesions were noted in any of the dose groups during necropsy examinations. The dose level of 3.5 LDU/kg can be considered as the Maximum Tolerated Dose (MTD).

Repeat dose studies of 13 and 39 weeks were conducted in the Cynomolgus monkey where incobotulinumtoxinA was administered intramuscularly in 4-12 week intervals (dose levels of up to 16 LDU/kg). Study results revealed local effects related to the pharmacological properties of
the drug. The only systemic effects were transient dose-dependent reductions in mean body weight or body weight gain.

In the 39-week toxicity study where Cynomolgus monkeys received repeated intramuscular injections of incobotulinumtoxinA in the left gastrocnemius and biceps brachialis muscles (dose of 16 LDU/kg with varying dosing intervals of up to 12 weeks for a total of 4 administrations) the occurrence of atrophy seemed to be time-related, and not specifically related to the number of administrations. Pronounced atrophy was observed following 4 intramuscular administrations of 16 U/kg/administration. The NOAEL for this study was 16 LDU/kg for a dosing interval of at least 8 weeks.

Most effects seen in repeated dose toxicity studies were related to the pharmacological action of local muscle paralysis (i.e., reduced motility and muscular tonus, ataxia) or to generalized low-grade blockade of autonomic neurotransmission (piloerection, ptosis, lacrimation or mydriasis). No severe systemic effects or apparent organ toxicity were detected.

**Mutagenicity / Carcinogenicity**

Studies have not been performed to evaluate the carcinogenic and mutagenic potential of incobotulinumtoxinA. Based on the chemical structure and mode of action there is no reason to suspect mutagenic or carcinogenic potential. Studies conducted with Active Comparator 1 have indicated no mutagenic potential.

**Reproductive and Developmental Toxicity**

**Fertility and Early Embryotic Development**

The effects of incobotulinumtoxinA on gonadal function, mating behaviour and reproductive performance were assessed after repeated intramuscular administration in rabbits at doses of 1.25, 2.5 and 3.5 LDU/kg. There were no effects of these parameters at any dose level given therefore 3.5 LDU/kg was considered the NOAEL under the defined experimental conditions.

**Embryo-foetal Development**

The effects of incobotulinumtoxinA on embryonic and foetal development of the rat were evaluated following intramuscular injections of total doses up to 98 LDU/kg during the period of organogenesis. A total dose of 30 LDU/kg (weekly 10 or biweekly 6 LDU/kg) was considered the maternal NOAEL. There were no indications of embryo-toxicity in any treated group except for a slight reduction in foetal weights in the groups where maternal toxicity resulted in reduced terminal maternal body weights. The total dose level of 98 or 90 LDU/kg (weekly 30, twice weekly 18 or daily 7 LDU/kg) was considered the NOAEL for embryo-toxicity.

Effects on embryo-foetal development were also evaluated in rabbits following multiple dose intramuscular administration of incobotulinumtoxinA at single dose levels of up to 5 LDU/kg. Maternal toxicity was observed at 2.5 and 5 LDU/kg. The maternal NOAEL was determined to be 1.25 LDU/kg after intramuscular administration during gestation. Abortions between GD 23 and 29 occurred in females at 5 LDU/kg; these were most likely associated with the observed maternal toxicity, as indicated by severe body weight loss in the affected females and the absence of embryo-fetal effects in the surviving dams. No indications of embryotoxicity or teratogenicity were seen at any of the dose levels tested, and therefore the single dose level of
5 LDU/kg was considered as the foetal NOAEL under the defined experimental conditions.

**Peri- and Post-natal Development**
The embryo-foetal, peri and post-natal development of the rat and the subsequent reproductive performance of the offspring was evaluated following repeated intramuscular doses of incobotulinumtoxinA from day 6 of gestation to weaning. There was no adverse effect of maternal treatment on pre- or post-natal development or reproductive performance of the offspring in any group. The NOAEL for the embryo-foetal and peri- and post-natal development of the rat and subsequent reproductive performance of the offspring was therefore weekly 20 (total of 120 LDU/kg) or daily 3 LDU/kg (total of 114 LDU/kg).

**Post-weaning Development in Juvenile Animals**
The effects of incobotulinumtoxinA on post-weaning development in juvenile rats were assessed after repeated intramuscular injections of up to 30 LDU/kg/administration at 2 week intervals up to 11 weeks of age. Dose-dependent decreases in size and weight of injected muscle, mean body weight gain, and food consumption were observed however there were no relevant effects on sexual maturation and post-weaning development. Reproductive performance was impaired and atrophy of the testicular germinal epithelium was seen at 30 LDU/kg, however, the affected males were not those that failed to mate. There were no adverse effects on mating performance or on the testicular germinal epithelium at lower dose levels. There were no indications of systemic toxicity other than growth retardation at a dose of 10 LDU/kg and below.

**Local Tolerance**
Local tolerance of incobotulinumtoxinA was assessed in mice, rabbits, and monkeys. Studies indicate that incobotulinumtoxinA does not induce clinically relevant local intolerance reactions after repeated intramuscular injection up to 40 LDU/kg or repeated intradermal administration up to 8.34 LDU/kg.

IncobotulinumtoxinA was also found to be non-irritating when administered via the ocular route in rabbits (100 LDU/animal).

**Hemolytic Activity**
In an *in vitro* study with pelleted human erythrocytes, incobotulinumtoxinA was not hemolytic at concentrations up to 400 LDU/mL (concentrations at least 400 times the maximal achievable concentration in human blood). Therefore, a hemolytic potential in human blood appears extremely unlikely.

**Antigenicity**
The antigenicity of incobotulinumtoxinA was examined in two repeated-dose studies in rabbits.

In the initial study the formation of neutralizing antibodies against the active neurotoxin was measured before, during and after five intradermal biweekly applications of a high dose (25 LDU per administration, approximately 8.34 LDU/kg) of incobotulinumtoxinA or Active Comparator 1. In study week 12, Botulinum neurotoxin type A-neutralizing antibodies were found in 4 of 8 surviving rabbits treated with Active Comparator 1 versus 0 of 10 surviving rabbits treated with incobotulinumtoxinA.
Results were confirmed with another study at lower doses where rabbits were administered incobotulinumtoxinA or Active Comparator 1 at 16 LDU per administration for 8 administrations, with a 25 LDU final booster administration over 33 weeks. An Active Comparator 2 treatment group was dosed at 40 LDU per administration for 5 administrations with a reduced dose of 20 LDU for the sixth (final) administration (due to an observed toxicity in terms of reduced body weight). After 6 injections 15 of 20 Active Comparator 2 sera were able to neutralize the paralytic activity of the neurotoxin. In test week 36, four of 20 animals treated with Active Comparator 1 had detectable neutralizing antibodies versus 0 of 20 animals administered incobotulinumtoxinA.
REFERENCES


12) Sassin I, Raschdorf A, Comes G. Study MRZ 60201-0410/1. Prospective, double-blind, placebo-controlled, randomized, multi-center trial with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spasticity of the upper limb. 2007.

PART III: CONSUMER INFORMATION

**XEOMIN®**

(incobotulinumtoxinA)

This leaflet is part III of a three-part “Product Monograph” published when XEOMIN® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about XEOMIN®. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
XEOMIN® is used for the treatment of the following conditions in adults:
- eyelid spasm (blepharospasm) and spasm in one side of the face (hemifacial spasm)
- twisted neck (spasmodic torticollis)
- uncontrollable muscle stiffness and/or muscle tone in arms or hands after a stroke (post-stroke spasticity of the upper limb).

What it does:
XEOMIN® is a medicine that relaxes the muscles.

When it should not be used:
- if you are allergic (hypersensitive) to Botulinum neurotoxin type A or any of the other ingredients of XEOMIN®
- if you suffer from generalised disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome)
- if an infection or inflammation is present at the injection site.

What the medicinal ingredient is:
incobotulinumtoxinA (purified neurotoxin free from complexing proteins)

What the important nonmedicinal ingredients are:
Human serum albumin, Sucrose (Sugar)

What dosage forms it comes in:
White powder for solution for injection, 50 or 100 LD₅₀ units per vial

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions
If you develop swallowing difficulties, speech or breathing disorders, please contact medical emergency services or ask your relatives to do so.

Before you use XEOMIN®, talk to your doctor or pharmacist if:
- you suffer from any type of bleeding disorders
- you receive substances that prevent the blood from clotting (anticoagulant therapy)
- you suffer from pronounced weakness or decreased muscle volume in the muscle where you will receive the injection
- you suffer from a disease called amyotrophic lateral sclerosis. This disease leads to a wasting of muscle tissue.
- you suffer from any disease that disturbs the interaction between nerves and skeletal muscles (peripheral neuromuscular dysfunction)
- you have or have had swallowing difficulties.
- you have or have had speech or breathing difficulties
- you are allergic or sensitive to XEOMIN®

In cases of repeated injections with XEOMIN®, the therapeutic effect of the product may vary. The possible reasons for an increase or decrease are:
- different techniques of preparation of the product by your doctor
- different treatment intervals
- injections into another muscle
- marginally varying effectiveness of the active substance of XEOMIN®
- non-response/therapy failure during the course of treatment.

The use of XEOMIN® in children and adolescents has not yet been investigated and is therefore not recommended.

XEOMIN® should only be given by physicians with the appropriate qualifications and experience in the treatment and use of the required equipment.

Seek immediate medical care if swallowing, speech or respiratory problems arise.

Pregnancy and breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine.

If you are pregnant or breast-feeding, XEOMIN® should not be used, unless you and your doctor together discuss your particular situation and agree that there is a clear necessity, and the potential benefit justifies the risk.

Driving and using machines
Before you perform tasks which may require special attention, wait until you know how you respond to XEOMIN®. If you feel loss of strength, muscle weakness, blurred vision, tiredness, dizziness or drooping eyelids, you should avoid these tasks while feeling this way.

INTERACTIONS WITH THIS MEDICATION
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Theoretically, the effect of XEOMIN® may be increased by:
- aminoglycoside antibiotics
- medicinal products that interfere with the transfer of an impulse from a nerve to a muscle, e.g. tubocurarine-type muscle relaxants that weaken the muscles.

Therefore, the concomitant use of XEOMIN® with aminoglycosides or spectinomycin requires special care. This is also relevant for medicinal products that weaken the muscle. Your doctor may reduce the starting dose of relaxant, or use an intermediate-action substance rather than substances with longer lasting effects.

Theoretically, the effect of XEOMIN® may be reduced by:
- certain anti-malaria/ anti-rheumatic medicines (4-Aminochinolines)

### PROPER USE OF THIS MEDICATION

**Usual dose:**
XEOMIN® may only be used by health care professionals experienced in the application of Botulinum toxin.

Dissolved XEOMIN® is intended for injections into the muscle.

The optimum dosage and number of injection sites in the treated muscle will be chosen by your doctor individually for you. The results of initial treatment with XEOMIN® should be evaluated and may lead to dose adjustment until the desired therapeutic effect is achieved.

If you have the impression that the effect of XEOMIN® is too strong or too weak, let your doctor know. In cases where no therapeutic effect is apparent, alternative therapies should be taken into consideration.

Your body may develop antibodies after you received Botulinum toxin type A preparations. Antibodies may reduce the therapeutic effectiveness of the product.

**Eyelid spasm (blepharospasm)**
Please inform your doctor prior to any treatment, if you:
- have had an eye surgery. Your doctor will then take additional precautions.
- are at risk of developing a disease called angle closure glaucoma. This disease can cause the inner eye pressure to rise and may lead to a damaging of your optic nerve. Your doctor will know if you are at risk.

Usually, the first onset of effect is observed within four days after injection. The effect of each treatment generally lasts for about 3-4 months; however, it may last significantly longer or shorter. The period between each treatment session is recommended to be at least 12 weeks. You should contact your doctor for retreatment when you feel the treatment is wearing off as there can be flexibility in terms of re-treatment intervals. Your doctor will determine if retreatment is necessary and may decide the intervals between treatments.

**Twisted neck (spasmodic torticollis)**
Usually, the first onset of effect is observed within seven days after injection. The effect of each treatment generally lasts for about 3-4 months; however, it may last significantly longer or shorter. The period between each treatment session is recommended to be at least 12 weeks. You should contact your doctor for retreatment when you feel the treatment is wearing off as there can be flexibility in terms of re-treatment intervals. Your doctor will determine if retreatment is necessary and may decide the intervals between the treatments.

**Uncontrollable muscle stiffness and/or muscle tone in arms or hands after a stroke (post-stroke spasticity of the upper limb).**
Usually, the first onset of effect is observed within four days after injection. The effect of each treatment generally lasts for about 3 months; however, it may last significantly longer or shorter. You should contact your doctor for retreatment when you feel the treatment is wearing off. Your doctor will determine if retreatment is necessary. Retreatment is possible but not more often than every 12 weeks.

**Overdose:**
Symptoms of overdose are not apparent immediately after the injection and may include general weakness, drooping eyelid, double vision, swallowing and speech difficulties, and pneumonia.

In case you feel symptoms of overdose please seek medical emergency services immediately or ask your relatives to do so, and have yourself admitted to hospital. Medical supervision for up to several days and assisted ventilation may be necessary.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

### SIDE EFFECTS AND WHAT TO DO ABOUT THEM

**General**
Like all medicines, XEOMIN® can cause side effects, although not everybody gets them.
Side effects may occur from misplaced injections of XEOMIN® temporarily paralysing nearby muscle groups. Large doses may cause paralysis in muscles distant to the injection site. Usually, side effects are observed within the first week after treatment and are temporary in nature. They may be restricted to the area around the injection site (e.g. local pain, tenderness at the injection site, and injection site hemorrhage).

As with any medicine, an allergic reaction may occur with XEOMIN®. An allergic reaction can cause any of the following symptoms:

- difficulty in breathing
- swelling of the hands, feet, ankles, face, lips, mouth or throat.

**If you develop swallowing difficulties, speech or breathing disorders, please contact medical emergency services immediately or ask your relatives to do so.**

**Blepharospasm**

During treatment, small punctuated bleedings may occur in the soft tissues of the eyelid. Your doctor can limit these by immediately applying gentle pressure at the injection site.

Common side effects reported include: drooping eyelid, dry eye, dry mouth, blurred vision, injection site pain, bruising at the injection site, vision impairment, lip or speech disorder, double vision, eye pain, tearing, difficulty swallowing, nausea, headache, and fatigue. Uncommon side effects include: paralysis of surrounding eye muscle and/or face muscles, itchy eye, muscle weakness, numbness or tingling feeling, bruising around the eye, and skin lesions.

After you receive a XEOMIN® injection into your muscle around your eye, your blinking rate may be reduced. This can lead to a prolonged exposure of the transparent front part of the eye (cornea). This exposure may lead to a damaging of the surface and an inflammation (corneal ulceration). This can occur more often if you suffer from disorders of your facial nerves.

**Twisted neck (spasmodic torticollis)**

After the injection you may develop swelling, soreness or bruising where the injection was given.

Common side effects include swelling difficulties, neck pain, muscle weakness, injection site pain, muscle and skeletal pain, muscle stiffness, muscle spasm, headache, nausea, dry mouth, weakness, increased sweating, dizziness, and feeling faint. Uncommon side effects include: speech disorder, difficulty breathing, involuntary head nodding, numbness or tingling feeling, pain, eye pain, inflammation of the colon, skin rash, skin redness, itching, flu syndrome, and runny nose.

In rare cases swallowing difficulties may lead to problems with breathing and you may have a higher risk of inhaling foreign substances or fluids. Foreign substances in your lungs may lead to an inflammation or infection (pneumonia).

If you cannot swallow your doctor will give you special medical treatment if needed (e.g. in the form of artificial nutrition). Swallowing difficulties can last for up to two to three weeks after injection; for one patient a duration of up to five months is known.

Inform your physician immediately of any swallowing difficulties.

**Uncontrollable muscle stiffness and/or muscle tone in arms or hands after a stroke (post-stroke spasticity of the upper limb)**

XEOMIN® can be used to treat uncontrollable muscle stiffness and cramps in parts of your limb, e.g. your elbow, forearm or hands. XEOMIN® is effective in combination with the usual treatment methods. XEOMIN® should be used together with these other methods. If you suffer from a shortening of your muscles at a joint (a fixed contraction) your doctor may choose not to give you XEOMIN®.

Common side effects include: headache, partial loss of sensation, skin sensations of heat, numbness, tingling or pain, feeling hot, difficulty swallowing, injection site pain, muscle weakness and pain in extremity.

*This is not a complete list of side effects. For any unexpected effects while taking XEOMIN®, contact your doctor or pharmacist.*

**HOW TO STORE IT**

Keep out of the reach and sight of children.

XEOMIN®, unreconstituted is stored at room temperature (up to 25°C). Once reconstituted with physiological saline, it may be stored for up to 24 hours at 2 to 8°C.
REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
  Health Canada
  Postal Locator 0701E
  Ottawa, Ontario
  K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found by contacting Merz Pharma Canada at 1-866-815-8715.

This leaflet was prepared by Merz Pharmaceuticals GmbH.

Last revised: December 22, 2015